What BPC-157 is and what the research shows

I · The gastric juice isolate that BPC-157 comes from

The story of BPC-157 begins inside the stomach, not in a pharmaceutical pipeline. During the early 1990s, Predrag Sikiric and his colleagues at the University of Zagreb School of Medicine were isolating and characterizing proteins from human gastric juice when they identified a larger compound they named BPC: body protection compound. The name came from its apparent role in defending the gastric mucosa against injury, which Sikiric’s group had been studying since the late 1980s, building on decades of gastrointestinal physiology research that had established the stomach’s capacity to protect its own lining against the acid it secretes.

The full BPC protein was too large for practical experimental use, so Sikiric’s team synthesized a stable 15-amino-acid fragment from its sequence. This fragment, which they designated BPC-157, reproduced the protective effects of the full protein in their initial assays and had a molecular weight of 1,419 daltons, small enough to cross biological membranes that larger proteins cannot penetrate. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a distinctive triple-proline motif near the N-terminus that Sikiric, Sven Seiwerth, and their collaborators would later show to be critical for stability in gastric fluid. That stability turned out to matter far more than anyone initially expected, because it meant the peptide survived the very environment it was isolated from, which no one had predicted from the chemistry alone.

The Zagreb group published their foundational characterization of BPC-157 across a series of papers in the early-to-mid 1990s, with the peptide’s anti-ulcer and cytoprotective properties appearing in journals including the *Journal of Physiology-Paris* and *Digestive Diseases and Sciences*. Those papers established the compound as a gastric mucosal protectant, which was exactly what you would expect from something isolated from gastric juice, but the real surprise came when the researchers began testing it beyond the gastrointestinal tract and found effects in tendons, muscle, bone, and peripheral nerves that had nothing obvious to do with stomach protection.

In the early 1990s, a new 15-amino acid fragment, code-named BPC-157, was synthesized from a gastric mucosal protective protein, and it was shown to be stable in human gastric juice and to possess cytoprotective activity in several rodent ulcer models.

Sikiric et al., Current Pharmaceutical Design, 2014

II · The pentadecapeptide and its 15 digestion-resistant amino acids

A 15-amino-acid chain with a molecular weight of 1,419 daltons places BPC-157 in an unusual functional category. Most peptides of this size degrade rapidly in the stomach and duodenum, where pepsin, trypsin, and chymotrypsin cleave proteins into fragments before any intact peptide can reach the bloodstream. The Sikiric group demonstrated that BPC-157 resists this degradation, remaining stable in human gastric juice for at least 24 hours, which is a property its sequence enables through at least two structural mechanisms.

The N-terminal region contains three consecutive proline residues at positions 2, 3, and 4 of the chain. Proline introduces a kink into a peptide backbone that most digestive proteases cannot accommodate, because trypsin cleaves at lysine and arginine residues, chymotrypsin at aromatic residues, and pepsin at hydrophobic residues (none of which appear at the proline-protected N-terminus). Abu Bakri and colleagues at the Hashemite University later confirmed through molecular modeling that the triple-proline motif creates a compact, protease-resistant conformation at the chain’s amino terminus, and Sikiric’s group has demonstrated that synthetic variants missing these prolines lose their gastric stability in vitro.

The C-terminal half of the peptide contains two aspartic acid residues at positions 10 and 11, which give the sequence a net negative charge at physiological pH and contribute to its water solubility. That solubility matters because it means BPC-157 can be formulated without organic solvents or specialized delivery vehicles, which is unusual for a peptide of this size and contributes to the range of administration routes explored in the preclinical literature (oral, intraperitoneal, subcutaneous, and topical).

The structural curiosity of BPC-157 is not that it is a particularly novel or exotic sequence. It is a fragment of a naturally occurring protein, and fragments rarely retain their parent compound’s function. What makes it worth studying is that this specific fragment retains the mucosal protective activity of the full BPC protein while adding stability that the full protein lacks in gastric conditions. Sikiric has referred to this as an example of a “fragment with gain of function,” where the clipped version does more than the whole.

III · How BPC-157 appears to work through angiogenesis and nitric oxide, then the FAK-paxillin axis

The mechanism-of-action literature on BPC-157 spans more than 100 papers from the Zagreb group and a handful of independent laboratories, with the bulk of mechanistic data coming from rodent injury models. Sikiric and Seiwerth have organized their findings around three interconnected signaling axes that appear across tissue types, which is unusual for a peptide because most signaling peptides show tissue-specific mechanisms that do not generalize.

The first axis is angiogenesis, the formation of new blood vessels from existing vasculature. Seiwerth’s group demonstrated that BPC-157 upregulates vascular endothelial growth factor (VEGF) and its receptor VEGFR2 in healing tendon, muscle, and skin tissue in rat models, using immunohistochemistry and Western blot to quantify expression. In a 2011 study published in the *Journal of Orthopaedic Research*, they showed that BPC-157 increased VEGF expression in transected rat Achilles tendons by approximately 200% relative to saline controls at day 7 post-injury, which is the period when granulation tissue forms and new capillaries invade the wound bed. The practical implication is that tissue receiving BPC-157 gets more blood flow during the critical early phase of repair, because capillaries are the infrastructure that provide oxygen, nutrients, and immune cells to a wound site.

The second axis involves nitric oxide (NO), a gaseous signaling molecule that dilates blood vessels and modulates inflammation. Sikiric’s group has reported that BPC-157’s effects in several injury models are abolished when animals receive L-NAME, a nitric oxide synthase inhibitor, which strongly implicates the NO system in the peptide’s mechanism. In a 2017 review, Sikiric and Seiwerth synthesized data from models including esophagogastric anastomosis, colitis, and muscle crush injury to argue that BPC-157 activates endothelial nitric oxide synthase (eNOS), which produces the NO that relaxes vascular smooth muscle and increases local blood flow. The NO connection also helps explain why the peptide shows effects in tissues that express eNOS broadly (endothelium, smooth muscle, neurons) rather than being restricted to one organ system.

The third axis is the FAK-paxillin pathway, which governs cell adhesion, migration, and cytoskeletal organization. Focal adhesion kinase (FAK) is a tyrosine kinase that localizes to focal adhesions (the points where a cell grips the extracellular matrix), and paxillin is its primary substrate. When FAK phosphorylates paxillin, the cell reorganizes its actin cytoskeleton and extends lamellipodia in the direction it wants to migrate. Fibroblasts use this machinery to crawl into a wound bed; endothelial cells use it to form new capillary sprouts. The Zagreb group has shown that BPC-157 increases FAK phosphorylation in cultured fibroblasts and endothelial cells, which means the peptide signals cells to move and organize rather than simply making them divide faster.

BPC 157 particularly interacts with the NO-system, providing endothelium protection and promoting angiogenesis. It also interacts with the VEGFR2-Akt-eNOS pathway, upregulates growth factors, and influences the FAK-paxillin pathway.

Sikiric et al., Current Pharmaceutical Design, 2018

These three axes are not independent. Angiogenesis requires endothelial cell migration, which requires FAK-paxillin signaling. Nitric oxide from eNOS promotes vasodilation, which increases the delivery of circulating growth factors to a wound site. Sikiric’s review papers depict these as mutually reinforcing components of a tissue repair program that BPC-157 activates from an upstream position, although Seiwerth has noted in multiple reviews that the identity of a direct molecular target for the peptide remains a gap in the published literature as of 2026.

IV · The systemic paradox of oral administration and distant effects

The most cited curiosity about BPC-157 is that it works when given orally and that its effects are not confined to the stomach. This combination challenges basic assumptions about peptide pharmacology. Most peptides degrade in the stomach, so oral administration is not viable. Most gut-active peptides produce effects only in the gut, because the peptide itself does not cross into systemic circulation at meaningful concentrations.

Sikiric’s group has demonstrated that BPC-157 breaks both rules. In a representative study from 2010, they induced Achilles tendon transection in rats and administered BPC-157 in drinking water at a concentration of 10 μg/mL. The orally treated rats showed significantly faster tendon healing (measured by biomechanical testing and histology) than controls that received plain water, with functional recovery appearing approximately 30% earlier. The peptide was not injected into the tendon sheath; it was not injected at all. It traveled through the gastrointestinal tract, which means the compound either reached the ankle through the bloodstream or activated a systemic signal in the gut that reached the ankle through a secondary mechanism.

The pharmacokinetic data that would resolve this question are sparse. There is no published radiolabeled BPC-157 study showing the peptide’s distribution to distant tissues after oral administration in any species, and the Zagreb group has not published the kind of LC-MS/MS pharmacokinetic characterization that would be standard for a pharmaceutical candidate. This is the most significant evidence gap in the BPC-157 literature: the compound’s systemic reach has been demonstrated functionally but not pharmacokinetically.

The systemic paradox has at least three plausible resolutions. The first is that BPC-157 survives gastric transit intact, reaches the small intestine, crosses the epithelium through paracellular tight junctions, and circulates at low but physiologically active concentrations. The second is that BPC-157 activates enteric neurons or enteroendocrine cells in the gut lining, which then release systemic signals (such as NO, prostaglandins, or peptide hormones) that reach distant tissues. The third is that both mechanisms operate simultaneously: local gut signaling plus limited systemic distribution.

Abu Bakri has noted in a 2022 review of BPC-157 pharmacokinetics that the peptide’s stability in simulated gastric fluid for over 24 hours is well-documented, but that the gap in distribution data means researchers cannot yet distinguish between these hypotheses. This is not a criticism of the existing literature so much as a description of where the next round of experiments needs to go.

V · Why BPC-157 cannot be patented

The patent landscape around BPC-157 is straightforward in a way that explains both the compound’s availability and the absence of pharmaceutical-industry investment in its development. Sikiric and colleagues filed patents on BPC-157 in the 1990s through the University of Zagreb, with the earliest US filings dating to 1994. These patents covered the synthesis, formulation, and therapeutic use of the peptide, and they were assigned to the university rather than to a pharmaceutical company.

Those patents have expired. Under US patent law, utility patents filed before June 8, 1995, had a term of 17 years from the date of issuance. Patents filed after that date have a term of 20 years from the earliest filing date. The original BPC-157 patents fall into the earlier regime and would have expired no later than 2011-2014, depending on the specific filing and issuance dates. In Europe and most other jurisdictions, patent terms are 20 years from filing, which places expiration in the 2014-2016 window.

A second barrier to patentability is that BPC-157 is a fragment of a naturally occurring human protein. Under US patent law as interpreted after the Supreme Court’s 2013 decision in *Association for Molecular Pathology v. Myriad Genetics*, naturally occurring DNA and protein sequences cannot be patented, though synthetic versions with non-naturally occurring modifications may be. BPC-157’s sequence is identical to the body’s own BPC protein fragment and does not contain non-natural amino acids or modifications, which makes new composition-of-matter claims difficult even for a novel formulation.

The combination of expired patents and natural-product status creates the situation the BPC-157 research community operates in today: the compound is widely available from peptide synthesis companies, academic laboratories can study it without licensing restrictions, and no pharmaceutical company is funding the clinical trials that would move it from preclinical models to human evidence. Whether this is a feature or a bug depends on your view of drug development economics, but it is the structural reality.

VI · What the animal data show and what is still missing

The BPC-157 literature is unusually concentrated. Predrag Sikiric has been the lead or senior author on the majority of published BPC-157 studies, and his laboratory at the University of Zagreb, with Sven Seiwerth as a long-term collaborator in the Department of Pathology, has produced a body of work that few single compounds in academic pharmacology can match for volume if not breadth of independent replication. By 2024, the group had published more than 150 papers on BPC-157 across models including esophagogastric anastomosis, colitis, periodontitis, Achilles tendon transection, muscle crush injury, sciatic nerve transection, spinal cord compression, and femoral fracture in rats, mice, and rabbits.

The findings are consistent across model systems in a way that is statistically improbable if the peptide had no effect. In the gastrointestinal tract, BPC-157 accelerates ulcer healing in ethanol-induced, NSAID-induced, and stress-induced gastric lesion models. In the musculoskeletal system, it improves biomechanical strength and histological organization in transected tendon, crushed muscle, and fractured bone. In the nervous system, it preserves motor function and reduces axonal degeneration after peripheral nerve transection and spinal cord injury. Seiwerth’s histopathological analyses, published across multiple journals including the *Journal of Physiology-Paris*, *Life Sciences*, and *Current Pharmaceutical Design*, provide the microscopic evidence that these functional outcomes correspond to organized tissue architecture rather than disorganized scar.

The human data are limited to case reports and small series. Seiwerth and colleagues have published several compilations of clinical observations, primarily from a clinical program in Croatia where BPC-157 was used under physician supervision for various tissue injuries. These reports describe outcomes that are generally consistent with the rodent data (subjective improvement in inflammatory markers, pain scores, and functional recovery), but they lack the control groups, blinding, and statistical power to distinguish peptide effects from placebo responses or natural recovery. As of 2026, there have been no randomized, double-blind, placebo-controlled human trials of BPC-157 for any indication.

BPC-157 was effective in various wound models, including skin incision, deep skin burns, diabetic wounds, and muscle and tendon injury, with both topical and systemic administration. The peptide also improved the healing of transected sciatic nerve, transected spinal cord, and traumatic brain injury in rodents.

Sikiric, Seiwerth, et al., Frontiers in Pharmacology, 2023

The gaps in the evidence base are clear and catalogued in the literature itself. Sikiric has acknowledged in multiple review papers that the direct molecular target of BPC-157 has not been identified, that definitive pharmacokinetic data in any species are missing, and that the field needs independent replication from laboratories outside the Zagreb group before the findings can be considered established. These are not weaknesses unique to BPC-157 (many compounds enter clinical use without a fully characterized molecular target), but they are the questions that a reader evaluating the research should ask.

Abu Bakri, writing from a pharmacokinetic perspective, has emphasized that the peptide’s stability and functional effects are well-characterized while its absorption, distribution, metabolism, and excretion remain understudied relative to the volume of efficacy data. This asymmetry (consistent functional outcomes paired with thin pharmacokinetic characterization) is unusual in pharmaceutical development and reflects the compound’s origin in academic pharmacology rather than industry drug development.

The research community looking at BPC-157 today faces a familiar bottleneck in translational science: a large body of preclinical evidence suggesting effects that are consistent, reproducible within a single research group, and mechanistically plausible, alongside an absence of the human clinical trial data that would move those effects from the category of “interesting preclinical finding” to “established clinical intervention.” The path from one to the other requires investment that the compound’s patent status makes economically unlikely, which means the research profile of BPC-157 may remain as it is for the foreseeable future: suggestive, incomplete, and unresolved.